Comprehensive GLP-1 Medication Support This tool features dedicated support for GLP-1 medications, including reminders, dose tracking, symptom logging, and clear progress charts, alongside visualizations of medication levels and patterns across various health metrics
References 1 GanieMAVasudevanVWaniIABabaMSArifTRashidA
Typically, candidates for tirzepatide for weight loss include: Adults with a body mass index (BMI) of 30 kg/m or greater (classified as obesity) Adults with a BMI of 27 kg/m or greater who also have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol Tirzepatide is not intended for individuals with a personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia syndrome type 2, or anyone with a known hypersensitivity to the medication
GLP-1 weight loss is a breakthrough for patients seeking a medically sound, sustainable solution
4 The ACC document additionally provided a series of opportunities in which clinicians may consider starting a GLP-1 RA or an SGLT-2 inhibitor with demonstrated cardiovascular benefit 4 : In a patient with T2D and ASCVD